Breaking News Instant updates and real-time market news.

MU

Micron

$25.58

-0.12 (-0.47%)

, RAD

Rite Aid

$4.87

0.14 (2.96%)

07:36
03/15/17
03/15
07:36
03/15/17
07:36

Unusual call flow in option market yesterday

Notable call activity was cited Tuesday in Micron (MU), Rite Aid (RAD), American Airlines (AAL), Delta Air Lines (DAL), Weatherford (WFT), Verifone (PAY), Aurinia Pharmaceuticals (AUPH), Platform Specialty Products (PAH), iKang Healthcare (KANG), and TG Therapeutics (TGTX).

MU

Micron

$25.58

-0.12 (-0.47%)

RAD

Rite Aid

$4.87

0.14 (2.96%)

AAL

American Airlines

$41.21

-1.16 (-2.74%)

DAL

Delta Air Lines

$46.28

-1.07 (-2.26%)

WFT

Weatherford

$5.98

-0.34 (-5.38%)

PAY

Verifone

$19.14

0.13 (0.68%)

AUPH

Aurinia Pharmaceuticals

$7.90

-2.64 (-25.05%)

PAH

Platform Specialty Products

$13.00

0.01 (0.08%)

KANG

iKang Healthcare

$14.91

-0.47 (-3.06%)

TGTX

TG Therapeutics

$13.15

0.95 (7.79%)

  • 15

    Mar

  • 17

    Mar

  • 19

    Mar

  • 20

    Mar

  • 23

    Mar

  • 06

    Apr

  • 22

    Apr

  • 14

    Mar

MU Micron
$25.58

-0.12 (-0.47%)

03/02/17
NEED
03/02/17
NO CHANGE
Target $42
NEED
Buy
Micron price target raised to $42 from $33 at Needham
Needham analyst Rajvindra Gill raised his price target on Micron to $42 following the company's positive preannouncement.
03/14/17
NEED
03/14/17
DOWNGRADE
NEED
Hold
Mobileye downgraded to Hold from Buy at Needham
Needham analyst Rajvindra Gill downgraded Mobileye (MBLY) to Hold from Buy after Intel (INTC) announced its intention to acquire all of the former's outstanding ordinary shares for $63.54 per share. The analyst believes the deal clearly validates the ADAS and fully autonomous vehicle market, and views it as a positive read-through into the entire ADAS and automotive supply chain, namely ON Semiconductor (ON), Micron (MU), Cypress Semiconductor (CY), NXP Semiconductors (NXPI), NVIDIA (NVDA), Tower Semiconductor (TSEM), and Infineon (IFNNY).
03/02/17
STFL
03/02/17
NO CHANGE
Target $40
STFL
Buy
Micron price target raised to $40 from $34 at Stifel
Stifel analyst Kevin Cassidy raised his price target on Micron to $40 after the company raised its guidance for its Q2 earnings, revenue and gross margin. The firm has a Buy rating on Micron shares.
03/02/17
GSCO
03/02/17
NO CHANGE
GSCO
Buy
Micron positive preannouncement supports near-term earnings upside, says Goldman
Goldman analyst Mark Delaney said Micron's positive preannouncement supports his view of near-term earnings upside from better margins. Delaney expects additional earnings upside in the May and August quarters given the timing lag for better market pricing to impact contracts. The analyst has a Buy rating and a $29 price target on Micron shares.
RAD Rite Aid
$4.87

0.14 (2.96%)

01/30/17
LEER
01/30/17
NO CHANGE
LEER
Outperform
Walgreens Boots Alliance, Rite Aid transaction still in-process, says Leerink
Leerink analyst David Larsen notes that he has confirmed with Walgreens Boots Alliance (WBA) that the deal with Rite Aid (RAD) would only terminate if either party were to walk away, which would require a formal announcement. Therefore, the analyst believes "no news is good news," and that the transaction is still in-process and on track. He reiterates an Outperform rating on Walgreens Boots Alliance's shares.
01/20/17
01/20/17
NO CHANGE

Rite Aid-Walgreens deal closing 'way more likely than not,' says Cowen
After a Bloomberg article said that the FTC is concerned about the sale of Rite Aid (RAD) stores to Fred's (FRED) as a remedy to concerns about Walgreens' (WBA) takeover deal, Cowen analyst Charles Rhyee said that the report could reflect a split staff at FTC and the losing side making some noise or it could be a public negotiating tactic. Given the various paths forward, including litigation, Rhyee still thinks it is "way more likely than not" that this deal will ultimately close and views the weakness in Walgreens shares as a buying opportunity.
01/20/17
EVER
01/20/17
NO CHANGE
EVER
Rite Aid could trade to $3.50 or below if deal is not completed, says Evercore ISI
Evercore ISI analyst Ross Muken believes Rite Aid (RAD) could have "massive" downside and would likely trade to $3.50 or below if the acquisition by Walgreens Boots Alliance (WBA) were not completed. For Walgreens, Muken said, if the deal is not completed, it would be a modest negative given the synergy potential and time committed to deal closure, but he expects Walgreen not to sit on the capital for very long and would look for a combination of share repurchases and additional M&A in the not-too-distant future.
01/17/17
01/17/17
UPGRADE
Target $95

Outperform
AmerisourceBergen upgraded to Outperform at Leerink
As previously reported, Leerink analyst David Larsen upgraded AmerisourceBergen (ABC) to Outperform from Market Perform and raised his price target on the shares to $95 from $75. The analyst believes the odds of the Walgreens Boots Alliance (WBA)/Rite Aid (RAD) transaction going through have "increased substantially," and believes that the long-term partnership with Walgreens Boots Alliance will act as a positive driver for volumes. Long-term, Larsen believes that AmerisourceBergen will continue to benefit from growth in specialty, biosimilars, and generic launches, while recent commentary seems to indicate that generic deflation trends are moderating.
AAL American Airlines
$41.21

-1.16 (-2.74%)

02/22/17
02/22/17
NO CHANGE

Morgan Stanley would not dismiss possibility of Berkshire buying an airline
With Warren Buffett's Berkshire Hathaway (BRK.A) recently disclosing an increase to its overall airline exposure, making the firm a number one or two holder for each of the "Big 4," Morgan Stanley polled investors and found that about 60% do not expect this to be a step towards a full-scale acquisition. However, analyst Rajeev Lalwani said the prospect of Berkshire buying an airline is a possibility that is "not worth dismissing," citing the historical precedent of Buffett's involvement in the rail industry and eventual deal to buy Burlington Northern SantaFe in 2009. The top four U.S. airlines include American Airlines (AAL), Delta Air Lines (DAL), Southwest (LUV) and United Continental (UAL).
02/06/17
02/06/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CBS (CBS) upgraded to Overweight from Neutral at Atlantic Equities. 2. Delta Air Lines (DAL) was upgraded to Outperform from Market Perform and American Airlines (AAL) was upgraded to Market Perform from Underperform at Bernstein. 3. FedEx (FDX) upgraded to Outperform from Market Perform at Raymond James with analyst Patrick Tyler Brown saying he expects FedEx to stay ahead of eCommerce growth by investing, but does not see dollars of capital rising, and actually expects capex/sales to fall in coming years as sales grow. 4. U.S. Steel (X) upgraded to Buy from Hold with a $39 price target with analyst David Coleman saying earnings estimates are rising following bullish 2017 guidance. 5. Cabot Oil & Gas (COG) upgraded to Overweight from Neutral at JPMorgan with analyst Michael Glick citing improved visibility after FERC's issuance of the certificate for Atlantic Sunrise on Friday. The analyst raised his price target for the shares to $27 from $26. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/06/17
BERN
02/06/17
UPGRADE
BERN
Market Perform
American Airlines upgraded on valuation, positive trends at Bernstein
As noted earlier, Bernstein upgraded American Airlines to Market Perform from Underperform. Analyst David Vernon upgraded the stock based on valuation and positive industry revenue trends. Target to $43 from $42.
02/06/17
BERN
02/06/17
UPGRADE
BERN
Market Perform
American Airlines upgraded to Market Perform from Underperform at Bernstein
DAL Delta Air Lines
$46.28

-1.07 (-2.26%)

02/06/17
BERN
02/06/17
UPGRADE
BERN
Outperform
Delta upgraded on sector outlook, balance sheet, cash return at Bernstein
As noted earlier, Bernstein upgraded Delta Air Lines to Outperform from Market Perform. Analyst David Vernon expects the company to benefit from more favorable industry pricing, driven by near-term ceilings on capacity and higher load factors. Moreover, he thinks that increasing load factors will boost airlines' revenue ,and he is upbeat on Delta's balance sheet and cash return policies. Target $61.
03/13/17
UBSW
03/13/17
NO CHANGE
UBSW
Buy
Weakness in airline sector a buying opportunity, says UBS
UBS analyst Darryl Genovisi said the recent dip in airline shares provides a buying opportunity. The analyst noted most of the airlines have cut their PRASM guidance for Q1 and with the miss already priced in and a better outlook for Q2, investors should be buyers of the group. Genovisi prefers United Continental (UAL) followed by Delta (DAL) and Southwest (LUV).
WFT Weatherford
$5.98

-0.34 (-5.38%)

03/07/17
03/07/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Hyatt (H) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Thomas Allen saying shares are trading in-line with his price target adn offer more attractive risk/reward. 2. Noble Corp. (NE) upgraded to Buy from Neutral at Seaport Global with analyst Mark Brown citing valuation and expectations for a pickup in drilling later in 2017. 3. Weatherford (WFT) upgraded to Overweight from Equalweight at Capital One with analyst Luke Lemoine saying the hiring of Mark McCollum, Halliburton's (HAL) CFO, adds legitimacy and credibility to Weatherford's status as a turnaround story. 4. Bill Barrett (BBG) upgraded to Buy from Hold at Canaccord with analyst Stephen Berman saying he sees strong 2018 growth, a solid liquidity position, and said shares are almost 50% from its 52-week high. 5. TSMC (TSM) upgraded to Buy from Hold at HSBC with analyst Steven Pelayo saying he believes TSMC is reasserting its technology leadership. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/07/17
SPHN
03/07/17
NO CHANGE
SPHN
Underweight
Weatherford new CEO 'a step in the right direction,' says Stephens
Stephens analyst Christopher Denison says the addition of Mark McCollum as President and CEO of Weatherford is "a step in the right direction" toward improving the company's focus on operational execution. However, the analyst reiterates an Underweight rating on the shares as delivering on the previously announced multi-year strategic initiatives is important before becoming more positive, and as longer-term challenges associated with the balance sheet and product offerings loom relative to better-capitalized peers.
03/08/17
03/08/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Michaels (MIK) upgraded to Buy from Neutral at BofA/Merrill with analyst Denise Chai saying fundamentals have hit an inflection point. The analyst expects comps to improve in the second half as it is up against easy compares due to the disruption from adding flexible merchandise space to stores and the election. 2. AvalonBay (AVB) upgraded to Buy from Neutral at BofA/Merrill with analyst Juan Sanabria saying its diversified portfolio is well positioned relative to peers with its concentrated Class A, and urban core supply. 3. Weatherford (WFT) upgraded to Neutral from Sell at Clarksons Platou. 4. Bellatrix Exploration (BXE) upgraded to Speculative Buy from Hold at Canaccord with analyst Anthony Petrucci citing improved risk/reward profile. The analyst cited improved overall reserve levels and better than expected reserve value. Petrucci lowered his price target to C$1.50 from C$1.60 on Bellatrix Exploration shares. 5. ManTech (MANT) upgraded to Buy from Hold at Maxim with analyst Brian Kinstlinger saying he views the company's contract awards over the last two years as a sign that demand is strengthening and believes ManTech will gain market share. Trump administration policies will likely lead to strong market growth in 2018 and 2019, added Kinstlinger, who keeps a $44 price target on ManTech shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/08/17
CLKS
03/08/17
UPGRADE
CLKS
Neutral
Weatherford upgraded to Neutral from Sell at Clarksons Platou
PAY Verifone
$19.14

0.13 (0.68%)

03/10/17
BTIG
03/10/17
DOWNGRADE
BTIG
Neutral
Verifone downgraded to Neutral from Buy at BTIG
BTIG analyst Mark Palmer downgraded Verifone Systems to Neutral following the company's better than expeted Q1 results citing the recent rally in the shares. The analyst believes further upside in the shares "may be capped" in the near term as investors wait for market acceptance of Verifone's new product.
03/10/17
MSCO
03/10/17
NO CHANGE
Target $18
MSCO
Equal Weight
Verifone upside already priced in, says Morgan Stanley
Morgan Stanley analyst James Faucette said India tailwinds are well anticipated an reflected in Verifone's valuation. The analyst maintains an Equal Weight and said a further rerating is unlikely until there signs of recovery outside of APAC. Faucette has a $18 price target on Verifone shares, up from $16.
03/14/17
BTIG
03/14/17
NO CHANGE
BTIG
BTIG says Western Union positive reaction to MoneyGram news makes sense
BTIG analyst Mark Palmer said he believes the uptick in Western Union (WU) shares after the announcement of Euronet's (EEFT) offer to buy competitor MoneyGram (MGI) makes some sense as Euronet may be seen as less of a competitive threat than Alibaba's (BABA) Ant Financial, which previously struck a deal to buy MoneyGram, and the bid underscores the attractiveness and potential of the global remittance space. However, speculation that if Ant was unsuccessful in its effort to acquire MoneyGram it could look to acquire VeriFone (PAY) or Green Dot (GDOT) "makes less sense," said Palmer.
01/20/17
CHLM
01/20/17
NO CHANGE
Target $26
CHLM
Buy
Verifone price target raised to $26 from $22 at Craig-Hallum
Craig-Hallum analyst Brad Berning raised his price target for Verifone to $26 from $22 as confidence grows during 2017 that new products will drive growth in 2018 and beyond. With commerce moving from Silo-channel to Omni-channel and payments becoming more complex and merging with commerce, the analyst notes that these market dynamics along with its investments and unique positioning raise his conviction that Verifone will succeed in its vision. He reiterates a Buy rating on the shares.
AUPH Aurinia Pharmaceuticals
$7.90

-2.64 (-25.05%)

03/06/17
FBRC
03/06/17
NO CHANGE
FBRC
FBR sees 'prime' merger environment for biotechs under Trump
Potential tax reform and FDA policy changes under President Trump could "prime the pump" for acquisitions of clinical-stage biotech companies by Big Pharma, FBR Capital analysts led by Chris Meekins tell investors in a research note. These police moves, coupled with the repeal of some taxes associated with the Affordable Care Act, are likely to increase funds for companies looking to make acquisitions, the analysts contend. Within its coverage universe, FBR sees TESARO (TSRO), Agile Therapeutics (AGRX), Kite Pharma (KITE), Juno Therapeutics (JUNO), Acceleron Pharma (XLRN), Abeona Therapeutics (ABEO), Aurinia Pharmaceuticals (AUPH), Geron (GERN) and Genocea Biosciences (GNCA) as "primary targets for those looking to make acquisitions."
03/03/17
HCWC
03/03/17
NO CHANGE
Target $12
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $12 from $8 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target on Aurinia Pharmaceuticals to $12 from $8 after the company reported that treatment of lupus nephritis with voclosporin demonstrated a substantial further improvement at 48 weeks. Given this type of "rare" treatment effect change over time, Arce said his conviction has increased that voclosporin can quickly emerge as the new standard-of-care in lupus nephritis treatment and he keeps a Buy rating on Aurinia shares.
03/02/17
LEER
03/02/17
NO CHANGE
LEER
Aurinia Pharmaceuticals price target raised to $11 from $7 at Leerink
12/30/16
HCWC
12/30/16
NO CHANGE
Target $8
HCWC
Buy
Aurinia Pharmaceuticals target lowered to $8 from $10 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce lowered his price target for Aurinia Pharmaceuticals to $8 to reflect dilution from the company's just closed equity offering. The financing removes the funding overhang, Arce tells investors in a research note. Aurinia expects its current cash is now sufficient to get it through 2017, which allows it "enough time to be thoughtful in selecting and securing additional, non-dilutive funding options, including out-licensing deals," the analyst contends. He keeps a Buy rating on the shares.
PAH Platform Specialty Products
$13.00

0.01 (0.08%)

01/20/17
HCWC
01/20/17
INITIATION
Target $5
HCWC
Buy
Platform Specialty Products initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started Platform Specialty Products with a Buy rating and $5 price target. Inhaled nitric oxide therapy for pulmonary arterial hypertension alone offers upside to the current valuation, the analyst contends.
01/30/17
MSCO
01/30/17
INITIATION
Target $12
MSCO
Equal Weight
Platform Specialty Products initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Neel Kumar initiated Platform Specialty Products with an Equal Weight with a $12 price target. The analyst expects Platform's valuation discount to peers to remain until leverage is reduced over the next several years.
02/06/17
GSCO
02/06/17
INITIATION
Target $15
GSCO
Buy
Platform Specialty Products initiated with a Buy at Goldman
Goldman Sachs analyst Robert Koort started Platform Specialty Products with a Buy rating and $15 price target.
02/06/17
02/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. TechnipFMC (FTI) initiated with a Buy at Jefferies. 2. Barracuda (CUDA) initiated with a Buy at Needham. 3. Terex (TEX) resumed with a Neutral at Citi. 4. TESARO (TSRO) initiated with a Market Perform at Cowen. 5. Platform Specialty Products (PAH) initiated with a Buy at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
KANG iKang Healthcare
$14.91

-0.47 (-3.06%)

TGTX TG Therapeutics
$13.15

0.95 (7.79%)

03/13/17
RHCO
03/13/17
NO CHANGE
RHCO
TG Therapeutics data 'highly positive,' says SunTrust
SunTrust analyst Yatin Suneja says that the data on TG's CD20 antibody, TG-1101, was "highly positive." The analyst expects additional data on the drug due out in June to support its approval, and he thinks that the company has multiple potential positive turning points over the next 6-18 months. He raised his price target on the shares to $28 from $26 and keeps a Buy rating.
03/06/17
FBRC
03/06/17
NO CHANGE
Target $26
FBRC
Outperform
TG Therapeutics price target raised to $26 from $24 at FBR Capital
FBR Capital analyst Edward White raised his price target on TG Therapeutics price target raised to $26 after the company's Phase 3 GENUINE trial of TG-1101 plus ibrutinib in patients with CLL met its primary endpoint. The analyst keeps an Outperform rating on the stock.
03/06/17
RHCO
03/06/17
NO CHANGE
Target $26
RHCO
Buy
TG Therapeutics price target raised to $26 from $19 at SunTrust
03/07/17
LTCO
03/07/17
NO CHANGE
Target $30
LTCO
Buy
Ladenburg ups TG Therapeutics target to $30 after data
Ladenburg Thalmann analyst Matt Kaplan raised his price target for TG Therapeutics to $30 from $28 after the Phase 3 study of TG-1101 met its primary endpoint "with a highly statistically significant result." The analyst reiterates a Buy rating on the shares.

TODAY'S FREE FLY STORIES

GOOG

Alphabet

$910.67

-0.31 (-0.03%)

, GOOGL

Alphabet Class A

$926.18

-1.48 (-0.16%)

16:32
08/19/17
08/19
16:32
08/19/17
16:32
Periodicals
Google working on new tools to boost news subscriptions, WSJ reports »

Google is said to be…

GOOG

Alphabet

$910.67

-0.31 (-0.03%)

GOOGL

Alphabet Class A

$926.18

-1.48 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

SRE

Sempra Energy

$116.55

0.76 (0.66%)

, BRK.A

Berkshire Hathaway

$267,377.00

302 (0.11%)

16:27
08/19/17
08/19
16:27
08/19/17
16:27
Periodicals
Sempra Energy is third bidder for Oncor Electric, Bloomberg reports »

Sempra Energy (SRE) is…

SRE

Sempra Energy

$116.55

0.76 (0.66%)

BRK.A

Berkshire Hathaway

$267,377.00

302 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Sep

AAP

Advance Auto Parts

$93.26

0.41 (0.44%)

16:20
08/19/17
08/19
16:20
08/19/17
16:20
Periodicals
Advance Auto Parts hit wall on Q2 results, but turnaround intact, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FL

Foot Locker

$34.38

-13.32 (-27.92%)

, AAP

Advance Auto Parts

$93.26

0.41 (0.44%)

16:13
08/19/17
08/19
16:13
08/19/17
16:13
Periodicals
Retail stocks swings could provide opportunity, Barron's says »

This earnings season,…

FL

Foot Locker

$34.38

-13.32 (-27.92%)

AAP

Advance Auto Parts

$93.26

0.41 (0.44%)

LB

L Brands

$36.20

-1.35 (-3.60%)

URBN

Urban Outfitters

$19.27

0.33 (1.74%)

ROST

Ross Stores

$59.02

5.69 (10.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$32.67

-0.28 (-0.85%)

, BMY

Bristol-Myers

$56.42

-0.35 (-0.62%)

16:05
08/19/17
08/19
16:05
08/19/17
16:05
Periodicals
Pharmaceutical companies not the only ones with healthy dividends, Barron's says »

Most income investors are…

PFE

Pfizer

$32.67

-0.28 (-0.85%)

BMY

Bristol-Myers

$56.42

-0.35 (-0.62%)

CAH

Cardinal Health

$64.38

-0.78 (-1.20%)

PDCO

Patterson Companies

$36.45

-0.31 (-0.84%)

RMD

ResMed

$73.07

0.28 (0.38%)

ABC

AmerisourceBergen

$78.60

-1.34 (-1.68%)

UNH

UnitedHealth

$190.82

-1.88 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 27

    Aug

  • 28

    Aug

  • 06

    Sep

  • 08

    Sep

  • 08

    Sep

  • 11

    Sep

  • 11

    Sep

  • 13

    Sep

  • 18

    Sep

  • 20

    Sep

  • 21

    Sep

  • 24

    Sep

  • 09

    Nov

  • 05

    Mar

GDI

Gardner Denver

$21.97

-0.03 (-0.14%)

, KKR

KKR

$18.14

0.11 (0.61%)

15:54
08/19/17
08/19
15:54
08/19/17
15:54
Periodicals
Gardner Denver integrated strategy beginning to pay off, Barron's says »

Under KKR (KKR), who…

GDI

Gardner Denver

$21.97

-0.03 (-0.14%)

KKR

KKR

$18.14

0.11 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSI

Motorola Solutions

$87.37

0.24 (0.28%)

, T

AT&T

$37.37

-0.23 (-0.61%)

15:47
08/19/17
08/19
15:47
08/19/17
15:47
Periodicals
Public-safety broadband network may supplant Motorola systems, Barron's says »

FirstNet has tapped…

MSI

Motorola Solutions

$87.37

0.24 (0.28%)

T

AT&T

$37.37

-0.23 (-0.61%)

CCI

Crown Castle

$104.12

-0.02 (-0.02%)

SBAC

SBA Communications

$142.90

0.69 (0.49%)

AMT

American Tower

$140.00

0.35 (0.25%)

COMM

CommScope

$33.00

0.16 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 06

    Sep

LMT

Lockheed Martin

$299.20

-2.22 (-0.74%)

15:39
08/19/17
08/19
15:39
08/19/17
15:39
Periodicals
Lockheed Martin should benefit from boost in military outlays, Barron's says »

Large-cap defense stocks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

SBUX

Starbucks

$52.70

-0.34 (-0.64%)

15:26
08/19/17
08/19
15:26
08/19/17
15:26
Periodicals
Starbucks could jump 20%, Barron's says »

There were plenty of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 02

    Nov

  • 25

    Jan

MRK

Merck

$61.49

-0.35 (-0.57%)

, INTC

Intel

$35.01

-0.16 (-0.45%)

15:05
08/19/17
08/19
15:05
08/19/17
15:05
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

MRK

Merck

$61.49

-0.35 (-0.57%)

INTC

Intel

$35.01

-0.16 (-0.45%)

UA

Under Armour

$15.64

-0.64 (-3.93%)

UAA

Under Armour

$17.12

-0.69 (-3.87%)

CPB

Campbell Soup

$53.69

-0.27 (-0.50%)

JNJ

Johnson & Johnson

$132.63

-0.41 (-0.31%)

UTX

United Technologies

$115.48

-0.62 (-0.53%)

BX

Blackstone

$31.52

-0.08 (-0.25%)

JPM

JPMorgan

$90.74

0.09 (0.10%)

GM

General Motors

$34.83

-0.17 (-0.49%)

WMT

Wal-Mart

$79.31

-0.39 (-0.49%)

TSLA

Tesla

$347.46

-4.46 (-1.27%)

DIS

Disney

$100.70

-0.68 (-0.67%)

AMZN

Amazon.com

$958.47

-2.1 (-0.22%)

AET

Aetna

$154.45

-1.36 (-0.87%)

ANTM

Anthem

$191.02

-0.94 (-0.49%)

CNC

Centene

$83.49

-0.13 (-0.16%)

CI

Cigna

$177.03

-1 (-0.56%)

HNT

Health Net

HUM

Humana

$247.28

-0.38 (-0.15%)

MOH

Molina Healthcare

$59.63

0.12 (0.20%)

UNH

UnitedHealth

$190.82

-1.88 (-0.98%)

WCG

WellCare

$173.56

-2.2 (-1.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 24

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 31

    Aug

  • 05

    Sep

  • 06

    Sep

  • 07

    Sep

  • 08

    Sep

  • 11

    Sep

  • 12

    Sep

  • 22

    Sep

  • 22

    Sep

  • 26

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 12

    Oct

  • 08

    Nov

  • 16

    Nov

  • 20

    Feb

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

CTL

CenturyLink

$19.16

-0.22 (-1.14%)

, LVLT

Level 3

$52.69

-0.3 (-0.57%)

14:52
08/19/17
08/19
14:52
08/19/17
14:52
Hot Stocks
CenturyLink continues to expect acquisition of Level 3 to be complete by Q3 »

CenturyLink (CTL) said in…

CTL

CenturyLink

$19.16

-0.22 (-1.14%)

LVLT

Level 3

$52.69

-0.3 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

$105.80

-0.07 (-0.07%)

17:45
08/18/17
08/18
17:45
08/18/17
17:45
Hot Stocks
Kansas City Southern director Henry Maier buys 3,000 shares »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

RXII

RXi Pharmaceuticals

$0.58

-0.02 (-3.36%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on RXi Pharmaceuticals »

RXi Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

WIN

Windstream

$1.98

0.06 (3.13%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Hot Stocks
Windstream CEO acquires 25,381 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$2.44

-0.22 (-8.27%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRN

Trinity Industries

$28.20

-0.03 (-0.11%)

17:25
08/18/17
08/18
17:25
08/18/17
17:25
Hot Stocks
ValueAct raises stake inTrinity Industries to 11% from 9.8% »

As of this date, ValueAct…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTN

Lpath

17:11
08/18/17
08/18
17:11
08/18/17
17:11
Hot Stocks
Breaking Hot Stocks news story on Lpath »

Stonepine Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$48.63

0.12 (0.25%)

17:08
08/18/17
08/18
17:08
08/18/17
17:08
Hot Stocks
Progressive CFO sells 50,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$172.57

-0.32 (-0.19%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Thermo Fisher director sells 11,318 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

SMBC

Southern Missouri Bancorp

$31.18

-0.05 (-0.16%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Southern Missouri Bancorp and Southern Missouri Bancshares to merge »

Southern Missouri Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:58
08/18/17
08/18
16:58
08/18/17
16:58
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ended advisory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ending…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says never had…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:56
08/18/17
08/18
16:56
08/18/17
16:56
Hot Stocks
Icahn no longer special advisor to President Trump on regulatory reform issues »

Carl Icahn, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:55
08/18/17
08/18
16:55
08/18/17
16:55
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.